AIPAC and Efti; My Final Take, page-42

Didn't plan on posting again but my research has uncovered something worth sharing.

March 2016 - Ph2 AIPAC commences their run in component of the study, recruiting 6 patients at the 6mg efti dose level.

22/6/16 - All 6 patients recruited, and commencement of the 9 patient 30mg efti dose level begins.

22/12/16 - Immutep announces that all 15 patients have responded to the treatment in a safe manner, Which to me means they have been on the treatment for at least a few cycles. An update of the clinical trial occurred in Mid October 2016, which I believe is when the last patient of the 30mg cohort entered the study.

June 2017 - Data update on the 15 patients. 6 of the patients are still on the study. It's safe to assume that all 6 of the 6mg patients have progressed, Which is fine and expected. Which leaves 6/9 patients at the 30mg dose still going, and if the last patient in was in October 2016, that's 8 months. Factor in the patients prior to Ocotber 2016 who are still progression free, and the fact these patients may have lasted another month or so After June 2017 before progressing, you're looking at a PFS of about 10 months or so for the 30mg efti cohort. This lines up with what we know regarding the durability of response with Efti.

Importantly, these patients weren't pre treated with cdk treatment, So I think a downward adjustment of 2 months is fair to accommodate for this. This is because the median PFS for paclixatel alone is generally 5.8 months or so for cdk naive patients, but low 4s for patients who have been on cdk.

This to me makes me think we are headed for numbers around the following mark:

- Median PFS for the control arm of 3.8-4.2 months
- Median PFS for the combination arm of 7.8-8.2 months.

Make of the above what you will. We will know soon.